Oxagen Limited - Company & Market Research Reports

Oxagen Limited is a privately-held biopharmaceutical company that works in collaboration with Eleventa LLC to develop and commercialise OC000459 for the Russian and CIS markets. OC000459 is a once-daily oral CRTH2 antagonist which has demonstrated encouraging activity in the treatment of eosinophilic asthma and allergic rhinoconjunctivitis, and an excellent safety profile. Oxagen Limited was incorporated in 1996 and is based in Abingdon, United Kingdom.

From
From
From
Asthma - Pipeline Review, H2 2018 - Product Thumbnail Image

Asthma - Pipeline Review, H2 2018

  • Drug Pipelines
  • 639 Pages
From
Asthma - Pipeline Review, H1 2018 - Product Thumbnail Image

Asthma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 592 Pages
From
Atopic Dermatitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Atopic Dermatitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 379 Pages
From
From
  • 9 Results (Page 1 of 1)
Loading Indicator
adroll